Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Kodiak Sells Capped Royalty Right on Global Net Sales of KSI-301 for $225 million
Royalty Rate of 4.5% on Annual Net Sales Terminates after 4.5 times the Funded Amount Has Been Paid
Transaction Enables an Immediate Acceleration of Clinical, Manufactu... Biopharmaceuticals, Ophthalmology, Venture Capital Kodiak Sciences, age-related macular degeneration
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Opthalmology | Pharmaceuticals | Venture Capital